Omnigen
Ocular surface wound healing (e.g., corneal defects, ulcers, dry eye disease)
CommercialActive
Key Facts
Indication
Ocular surface wound healing (e.g., corneal defects, ulcers, dry eye disease)
Phase
Commercial
Status
Active
Company
About NuVision Biotherapies
NuVision Biotherapies is a private, commercial-stage biotech focused on regenerative medicine for ophthalmology. Leveraging its patented Tereo® preservation technology, the company has launched two key products: Omnigen, a ready-to-use amniotic membrane graft for wound healing, and OmniLenz, a custom contact lens for rapid, non-surgical care. Founded on 15 years of translational research from the University of Nottingham, NuVision is led by an experienced team with deep medical device industry expertise and is building a portfolio to address significant unmet needs in ocular surface disease.
View full company profile